Your browser doesn't support javascript.
loading
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma.
Zhou, Yang; Ray, Partho Sarothi; Zhu, Jianguo; Stein, Frank; Rettel, Mandy; Sekaran, Thileepan; Sahadevan, Sudeep; Perez-Perri, Joel I; Roth, Eva K; Myklebost, Ola; Meza-Zepeda, Leonardo A; von Deimling, Andreas; Fu, Chuli; Brosig, Annika N; Boye, Kjetil; Nathrath, Michaela; Blattmann, Claudia; Lehner, Burkhard; Hentze, Matthias W; Kulozik, Andreas E.
Affiliation
  • Zhou Y; Molecular Medicine Partnership Unit (MMPU), Heidelberg University and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Ray PS; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
  • Zhu J; Molecular Medicine Partnership Unit (MMPU), Heidelberg University and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Stein F; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
  • Rettel M; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Sekaran T; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Sahadevan S; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Perez-Perri JI; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Roth EK; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Myklebost O; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Meza-Zepeda LA; Molecular Medicine Partnership Unit (MMPU), Heidelberg University and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • von Deimling A; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
  • Fu C; Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Brosig AN; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Boye K; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Nathrath M; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Blattmann C; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
  • Lehner B; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hentze MW; Molecular Medicine Partnership Unit (MMPU), Heidelberg University and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Kulozik AE; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
Nat Commun ; 15(1): 2810, 2024 Apr 01.
Article de En | MEDLINE | ID: mdl-38561347
ABSTRACT
Osteosarcoma is the most common primary malignant bone tumor with a strong tendency to metastasize, limiting the prognosis of affected patients. Genomic, epigenomic and transcriptomic analyses have demonstrated the exquisite molecular complexity of this tumor, but have not sufficiently defined the underlying mechanisms or identified promising therapeutic targets. To systematically explore RNA-protein interactions relevant to OS, we define the RNA interactomes together with the full proteome and the transcriptome of cells from five malignant bone tumors (four osteosarcomata and one malignant giant cell tumor of the bone) and from normal mesenchymal stem cells and osteoblasts. These analyses uncover both systematic changes of the RNA-binding activities of defined RNA-binding proteins common to all osteosarcomata and individual alterations that are observed in only a subset of tumors. Functional analyses reveal a particular vulnerability of these tumors to translation inhibition and a positive feedback loop involving the RBP IGF2BP3 and the transcription factor Myc which affects cellular translation and OS cell viability. Our results thus provide insight into potentially clinically relevant RNA-binding protein-dependent mechanisms of osteosarcoma.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs osseuses / Ostéosarcome Limites: Humans Langue: En Journal: Nat Commun / Nature communications Sujet du journal: BIOLOGIA / CIENCIA Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs osseuses / Ostéosarcome Limites: Humans Langue: En Journal: Nat Commun / Nature communications Sujet du journal: BIOLOGIA / CIENCIA Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Royaume-Uni